

MILESTONES

- Founded, 2021
- \$1.5 M invested so far
- Development stage - Preclinical

FOUNDING TEAM

Prof. Ayala Pollack, MD

Founder, Chief Scientific Advisor & Board Member, retina specialist, researcher, and entrepreneur

Dr. Dana Rabinovich, PhD

Founder and CEO, Scientist, seasoned biotech executive, and entrepreneur

CONTACT

Dana Rabinovich
dana@ophtimedrx.com
(m) +972-52-6633794

PROBLEM

- Dry Age-related Macular Degeneration (AMD) is a chronic, aging, progressive eye disease
- Leads to central vision loss
- No available treatment

SOLUTIONS

OphtiMedRx develops anti-senescence (cellular aging) agent for the treatment of dry AMD. This treatment protects retinal cells from aging and can halt progression of dry AMD. Our cutting-edge therapy will prevent the loss of vision and independence and bring enormous benefit to patients.

MARKET

AMD is the leading cause of blindness in the industrial world - Major, growing market opportunity.

\$ 175 M

GLOBAL PREVALENCE
OF DRY AMD IN 2020

\$ 45 B

Economic Burden
(USA & EU)

\$ 18 B

EXPECTED MARKET
SIZE IN 2028

COMPETITIVE ADVANTAGES

A therapy for early stages and prevention of retinal damage. Other treatments under development target patients with advanced retinal damage.

High efficacy - clinical results of other investigated drugs suggest 30% efficacy only.

Simple, safe, and in-expensive way of use.

REVENUE MODEL

Consider two alternatives:

- Out-license the product or engage in a licensing agreement after the completion of a significant milestone.
- Complete the development and team up with manufacturing partners (big pharmaceutical companies) to manufacture and distribute the drug worldwide.